#Gastric Cancer Market Forecast

[healthcaretrends23]

The gastric cancer market size was valued at $2.1 billion in 2021, and is estimated to reach $10.7 billion by 2031, growing at a CAGR of 17.9% from 2022 to 2031.

[trendingreportz]

Antibody Production Market - Forecast(2024 - 2030)

 Overview

Antibody Production Market is projected to reach revenue of $22.5 billion by 2025, and is estimated to grow at a CAGR of 12.8% during the forecast period 2019-2025. The Antibody Production market size, in 2018, is $9.7 billion. Antibody production by various biotechnology companies is to make medicines or diagnostic tests. The antibodies are mainly used to develop treatments for cancer and diseases such as arthritis, sclerosis, and others.

Request Sample

Key Takeaways

The market is estimated to grow at a CAGR of 12.8% owing to the rising rate of infectious diseases and increasing investments by biotechnology companies to develop treatment for various chronic diseases.

Companies are adopting various strategic alliances to expand in various regions. Investments in antibody production and research have increased in order to develop treatment for deadly diseases such as cancer.

Cancer treatment is observed to be more effective when multiple methods are used. Treatment methods such as stem cell transplantation along with antibody treatment has improved the survival rate of patients. Advances in biotechnology and antibody production have led to the development of various therapies for common diseases.

Process - Segment Analysis

Downstream processing is having major share by revenue in the owing to the large use of chromatography systems and resins for antibody production.  This process is highly accurate, sensitive and effective, making its use popular for the production of antibodies. 

Inquiry Before Buying

Type - Segment Analysis

Main types of antibodies produced are monoclonal and polyclonal antibodies. Monoclonal antibodies are clones of the parent cell and Polyclonal antibodies are made from different cells. Monoclonal antibodies are dominant segment compared to polyclonal antibodies and have a CAGR of 11.2%. They are having more demand for treatment of infections, cancer, and other chronic diseases. A common method of preparation of monoclonal antibodies is using ion exchange chromatography. This is because with this method, the process can be controlled easily and has high capacity or purification capability. Ammonium sulfate precipitation is used for monoclonal and polyclonal isolation.

End-User - Segment Analysis

Pharmaceutical and biotechnological companies are having larger share by end-user segment. This is because of the production of antibodies especially for these companies and due to the high investment for research and development by such companies. 

Schedule a Call

Geography - Segment Analysis

North America accounts for largest Antibody Production market share with 32.3% in 2018. This is owing to the presence of various biotechnology companies present here. Also, the government expenditure for healthcare sector in North America is high. These factors contribute to the growth of the market in this region. However, Asia Pacific will have higher growth rate in the coming years due to supportive regulations and increasing innovations by the companies here.

Drivers – Antibody Production Market

·      Rising rate of chronic diseasesAntibodies protect body by strengthening the immune system. They are used to prevent virus or bacteria related diseases. Antibodies are produced for various infections and are given to people as immunizations. They are also being developed for treatment of cancer and arthritis. Gastric cancer is said to be the second leading cause of global cancer-related deaths. Thus the antibody production will contribute to gastroenterology. The major gastric cancer treatment antibodies include Ramucirumab and Trastuzumab.

·         Increase in expenditure by biotechnology companies

Biosimilars are gaining popularity as they serve the same purpose as the biologic and are also less expensive. With many patent expirations in the coming years, the biotechnology companies are investing in development of biosimilars. They are also increasing expenditure for research and developments for antibody production processes.

Buy Now

Challenges – Antibody Production Market

·         High cost of production

Antibody production requires heavy expense by the companies. Their expenditure and investments for antibody production will be high. The high cost for antibody production will challenge the market.

Antibody Production Industry Outlook

Research & development along with strategic alliances are some of the key strategies adopted by players in the Antibody Production market. Antibody Production Market top 10 companies are Cellab Gmbh, Eppendorf Ag, Integra Bioscience Ag, Merck Kgaa, Pall Corp, Sartorius Ag, Thermo Fisher Scientific, Inc, ProteoGenix, Genentech, Inc. and BIOTEM.

Antibody Production Market Research Scope:

The base year of the study is 2018, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. These provide the key market participants with the necessary business intelligence and help them understand the future of the Antibody Production Market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. 

[credenceresearchdotblog]

The HER2 gastric cancer market is set for a steady ascent from 2024 to 2032, with a compound annual growth rate (CAGR) of 3.12%. The market’s size in 2024 is 1340.56 million USD, and it’s projected to escalate to 1714.07 million USD by 2032. Gastric cancer, a prevalent and often fatal malignancy, continues to pose a significant global health challenge. Among its various subtypes, HER2-positive gastric cancer has garnered considerable attention due to its distinct biological characteristics and therapeutic implications. HER2, or Human Epidermal Growth Factor Receptor 2, is a protein that promotes cell growth, and its overexpression in gastric cancer cells is associated with aggressive disease progression and poor prognosis. The HER2 gastric cancer market has evolved rapidly in recent years, driven by advancements in targeted therapies and personalized medicine, offering hope for improved patient outcomes.

Browse the full report at https://www.credenceresearch.com/report/her2-gastric-cancer-market

Market Dynamics

The HER2 gastric cancer market is shaped by a complex interplay of factors, including the rising incidence of gastric cancer, advances in diagnostic technologies, the development of targeted therapies, and growing awareness of personalized treatment approaches. According to the World Health Organization (WHO), gastric cancer is the fifth most common cancer worldwide, with over a million new cases diagnosed annually. Although HER2-positive gastric cancer represents only about 10-20% of these cases, the need for specialized treatments has spurred significant market growth.

Advancements in Diagnostics and Treatment

One of the key drivers of the HER2 gastric cancer market is the improvement in diagnostic capabilities. The introduction of more accurate and accessible testing methods, such as immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), has facilitated the identification of HER2-positive patients. Early and precise detection is crucial, as it allows for the timely initiation of targeted therapies, which can significantly improve survival rates.

The development of targeted therapies has revolutionized the treatment landscape for HER2-positive gastric cancer. Trastuzumab (Herceptin), the first HER2-targeted therapy approved for gastric cancer, has been a game-changer, improving overall survival in combination with chemotherapy. The success of Trastuzumab has paved the way for the development of other HER2-targeted agents, including pertuzumab, trastuzumab deruxtecan, and tucatinib, each offering different mechanisms of action and potential benefits.

Challenges and Opportunities

Despite these advancements, the HER2 gastric cancer market faces several challenges. One of the primary obstacles is the development of resistance to HER2-targeted therapies. Many patients eventually progress despite initial treatment success, necessitating the exploration of combination therapies and novel treatment strategies. Additionally, the high cost of targeted therapies can limit access, particularly in low- and middle-income countries, where the burden of gastric cancer is often highest.

However, these challenges also present opportunities for innovation. The ongoing research into overcoming resistance mechanisms has led to the investigation of new drug combinations and next-generation HER2 inhibitors. Furthermore, the integration of biomarker testing into routine clinical practice has the potential to refine patient selection and optimize treatment outcomes, ensuring that the right patients receive the most effective therapies.

Regional Market Insights

The HER2 gastric cancer market exhibits regional variations, reflecting differences in gastric cancer incidence, healthcare infrastructure, and access to advanced treatments. Asia-Pacific, particularly East Asia, represents the largest market due to the high prevalence of gastric cancer in countries like Japan, South Korea, and China. In contrast, North America and Europe have smaller patient populations but benefit from robust healthcare systems and greater access to innovative therapies.

In Asia-Pacific, the market is expected to grow rapidly due to increasing awareness, improved diagnostic capabilities, and the introduction of new targeted therapies. Governments in the region are also investing in cancer care infrastructure, which is likely to further boost market growth. Meanwhile, in North America and Europe, the focus is on expanding the use of combination therapies and overcoming treatment resistance, with ongoing clinical trials playing a pivotal role in shaping the future treatment landscape.

Future Outlook

The HER2 gastric cancer market is poised for continued growth as new therapies and diagnostic tools are developed and integrated into clinical practice. The trend towards personalized medicine, where treatments are tailored to the individual patient based on genetic and molecular profiling, is expected to drive innovation and improve outcomes for HER2-positive gastric cancer patients. Moreover, the increasing emphasis on combination therapies, addressing resistance mechanisms, and expanding access to targeted treatments in emerging markets will be crucial in shaping the future of this dynamic market.

Key Player Analysis:

Roche (Herceptin)

Merck (Keytruda)

AstraZeneca (Tagrisso)

Daiichi Sankyo (Enhertu)

Bristol Myers Squibb (Opdivo)

Genentech

MacroGenics

Seattle Genetics

Pfizer

Takeda

Segmentations:

By Therapy:

Chemotherapy

Immunotherapy

Radiation Therapy

Targeted Therapy

By Stage:

Stage I

Stage II

Stage III

Stage IV

By End-User:

Ambulatory surgery centers,

Hospitals and Specialty clinics

Others

Based on the Geography:

North America

US

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/her2-gastric-cancer-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[supriyab]

Lycopene Market to Record Steady Growth by 2025

The lycopene market is estimated to be valued at USD 126 million in 2020 and is projected to reach USD 161 million by 2025, at a CAGR of 5.0% during the forecast period. The increasing number of benefits offered by lycopene in preventive healthcare and its rising applications in an array of industries across the globe are projected to exponentially grow the lycopene market in the coming years.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=104131737

Lycopene is a carotenoid that gives some fruits and vegetables their red color. Lycopene is majorly present in tomato species known as Solanum lycopersicum, mostly found in Central and South American regions. It is a carotenoid and a phytonutrient substance, and is an essential antioxidant for the human body, which helps in protecting from degenerative diseases. Further, lycopene studies are associated with the prevention of diseases and conditions, including hypothesis, a number of cancers (prostate cancer, digestive tract cancer, bladder cancer, skin cancer, breast cancer, gastric cancer, and cervical cancer), cardiovascular diseases, osteoporosis & other bone disorder, male infertility, hypertension, and other human diseases; it is used in the treatment of various diseases such as human papilloma virus (HPV) infection, asthma, gingivitis, and cataracts, which has resulted in the significant expansion of the lycopene market over the last few years.

Lycopene can be sourced from synthetic as well as natural sources, and based on the source, the price and application of lycopene vary. The properties of lycopene are, however, independent of its source. The growing health concerns due to the consumption of synthetic ingredients have been restraining its adoption. Hence, the manufacturers have been shifting their product offering from synthetic sources to naturally extracted ingredients, and this trend has been witnessed to be true in the lycopene market as well.

Traditionally, the application of lycopene was limited to its use as a coloring agent. However, multiple clinical studies have proved its antioxidant and anti-inflammatory properties, and hence, the application of lycopene has broadened in multiple application industries. As a result, the application of lycopene has been growing as a health ingredient in the dietary supplement and functional food industries.

The lycopene market is growing exponentially in the Asia Pacific region, owing to the established manufacturers and the organized food industry in the region. Although the lycopene market was dominated by Europe, the market in Asia Pacific is projected to witness the highest growth rate due to its large population base and changing food consumption trends in emerging economies. Developing countries such as China, India, Indonesia, and Thailand have shown rapid growth in the dietary supplement and food industries. Also, the application of lycopene in the personal care & cosmetic industry is witnessing growth in these countries due to rising temperature and climatic conditions, causing the market to grow exponentially.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=104131737

Many domestic and global players provide lycopene as an ingredient across the world, making it a fragmented market. Major players have their presence in the Asia Pacific region, primarily in Chinese and Indian countries. Key players operating in this market include Allied Biotech Corporation (China), Lycored (Israel), DSM (Netherlands), Wellgreen Technology Co Ltd (China), Divi’s Laboratories (India), San-Ei Gen F.F.I., Inc (Japan), Dangshang Sannuo Limited (China), DDW (US), Döhler (Germany), Farbest Brands (US), Zhejiang NHU CO. Ltd (China), EID Parry (India), Shaanxi Kingsci Biotechnology Co. Ltd (China), Vidya Herbs (India), Xi'an Pincredit Biotech Co Ltd (China), Hunan Sunshine Bio-Tech Co.Ltd (China), Xi'an Natural Field Bio-Technology Co.,Ltd (China), Plantnat  (China), SV AgroFoods (India), and Plamed Green Science Group (China).

[trinitydigest]

HER2-Positive Gastric Cancer Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Pfizer, Hanmi Pharma, Bristol-Myers Squibb, Merck Sharp & Dohme

http://dlvr.it/T5HRsq

[newsheadlinesnow]

HER2-Positive Gastric Cancer Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Pfizer, Hanmi Pharma, Bristol-Myers Squibb, Merck Sharp & Dohme

http://dlvr.it/T5HB2f

[jayanthitbrc]

Fighting Global Rise: Cancer Monoclonal Antibodies Market Gears for Growth

The Cancer Monoclonal Antibodies by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033). Learn More On The Cancer Monoclonal Antibodies Market: https://www.thebusinessresearchcompany.com/report/cancer-monoclonal-antibodie-global-market-report According to The Business Research Company’s Cancer Monoclonal Antibodies, The cancer monoclonal antibodies market size has grown rapidly in recent years. It will grow from $59.98 billion in 2023 to $66.1 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%.  The  growth in the historic period can be attributed to  emerging markets growth, increase in r&d expenditure, increased geriatric population, and increased preference for biological treatments.. The cancer monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $95.99 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%.  The growth in the forecast period can be attributed to increasing prevalence of cancer, expanding global access, and rise in healthcare expenditure will drive the growth.. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer monoclonal antibody market. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. Get A Free Sample Of The Report (Includes Graphs And Tables): https://www.thebusinessresearchcompany.com/sample.aspx?id=3451&type=smp The cancer monoclonal antibodies market covered in this report is segmented – 1) By Monoclonal Antibody Therapies: Avastin, Herceptin, Keytruda, Opdivo, Darzalex, Perjeta, Others 2) By Application: Breast Cancer, Blood Cancer, Lung Cancer, Brain Tumor, Colorectal Cancer, Cervical Cancer, Gastric Cancer, Others 3) By End-User : Hospitals, Research Laboratories, Others Companies in the cancer monoclonal antibody market are increasing their product innovation through strategic collaborations. To sustain themselves in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with academic and research institutions in this market by way of partnerships and in- or out-licensing deals, this trend has been increasing over the past few years. The cancer monoclonal antibodies market report table of contents includes: 1. Executive Summary 2. Market Characteristics 3. Market Trends And Strategies 4. Impact Of COVID-19 5. Market Size And Growth 6. Segmentation 7. Regional And Country Analysis . . . 27. Competitive Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: info@tbrc.info Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: https://blog.tbrc.info/ Healthcare Blog: https://healthcareresearchreports.com/ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[credenceresearchdotblog]

The endoscopic ultrasound (EUS) needle market is projected to grow from USD 380.26 million in 2023 to USD 573.92 million by 2032, at a CAGR of 4.68%.Endoscopic Ultrasound (EUS) has become an indispensable tool in modern gastroenterology, blending endoscopy and ultrasound to provide detailed images and facilitate fine-needle aspiration (FNA) or biopsy of lesions within or adjacent to the gastrointestinal tract. EUS needles, pivotal to this procedure, have witnessed significant market growth owing to their critical role in diagnosing and staging gastrointestinal and other cancers. This article explores the key dynamics, trends, and future outlook of the EUS needles market.

Browse the full report at https://www.credenceresearch.com/report/endoscopic-ultrasound-eus-needles-market

Market Dynamics

Growing Prevalence of Gastrointestinal Diseases

The increasing incidence of gastrointestinal disorders, including pancreatic, gastric, and colorectal cancers, has driven the demand for EUS procedures. The ability of EUS to provide detailed images and facilitate targeted biopsies has made it a preferred diagnostic tool. This rising prevalence is a primary driver of the EUS needles market.

Technological Advancements

Technological innovations have significantly enhanced the safety, efficacy, and accuracy of EUS procedures. The development of needles with improved designs, such as the introduction of needles with echogenic tips, has improved visibility and accuracy during procedures. Additionally, the advent of fine-needle biopsy (FNB) needles has expanded the utility of EUS beyond aspiration, enabling histological examination.

Increasing Adoption of Minimally Invasive Procedures

The healthcare industry’s shift towards minimally invasive procedures is another critical factor propelling the EUS needles market. EUS is less invasive compared to traditional surgical methods, resulting in reduced patient recovery time, lower risk of complications, and cost savings. This trend aligns with the broader move towards minimally invasive diagnostics and therapeutics in the medical field.

Competitive Landscape

The EUS needles market is highly competitive, with key players focusing on product innovation, strategic collaborations, and mergers and acquisitions to strengthen their market position. Some of the prominent players include Olympus Corporation, Cook Medical, Medtronic, and Boston Scientific Corporation. These companies are investing in research and development to introduce advanced products and expand their product portfolios.

Future Outlook

The EUS needles market is poised for substantial growth in the coming years. The increasing prevalence of gastrointestinal diseases, technological advancements, and the growing adoption of minimally invasive procedures are expected to drive market expansion. Additionally, ongoing research and development activities aimed at improving the efficacy and safety of EUS needles will further fuel market growth.

Key Players

ACE Medical Devices Pvt. Ltd.

Boston Scientific Corporation

Cook Medical (Cook Group Incorporated)

CONMED Corporation

Endo-Flex GmbH

Fujifilm Holdings Corporation

Medi-Globe GmbH

Medtronic plc

Olympus Corporation

PENTAX Medical (Hoya Corporation)

ROCAMED

Sterylab S.r.l.

TaeWoong Medical Co., Ltd.

Wilson-Cook Medical Inc. (Cook Medical)

Xlumena, Inc. (Boston Scientific Corporation)

Others

Segmentations:

By Type

Aspiration Needles

Biopsy Needles

By Application

Enteral Needles

Bronchial Needles

By End-user

Hospital

Ambulatory Surgical Centers

Specialty Clinics

By Indication

Oncology

Gastroenterology

Pulmonology

Urology

Others

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

France

The U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of Middle East and Africa

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[omkarpatel]

The Global Atezolizumab Market will grow at highest pace owing to rising treatment of non-small cell lung cancer

The atezolizumab market consists of monoclonal antibody immunotherapy treatments targeting programmed death-ligand 1 (PD-L1). Atezolizumab was the first FDA-approved PD-L1 inhibitor for the treatment of non-small cell lung cancer (NSCLC). It has shown improved survival rates for NSCLC patients whose tumours express PD-L1. The Global Atezolizumab Market is estimated to be valued at US$ 308 Million in 2024 and is expected to exhibit a CAGR of 3.0% over the forecast period 2023 to 2030. Key Takeaways Key players operating in the atezolizumab market are Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc. These players are developing innovative drug formulations and focusing on clinical trials to expand the approved therapeutic areas of atezolizumab. The growing incidence of lung cancer, particularly NSCLC, is a major factor driving the demand for atezolizumab treatment worldwide. According to the World Health Organization, lung cancer is the leading cause of cancer deaths globally. Early diagnosis and introduction of targeted therapies like atezolizumab have improved lung cancer survival rates in recent years. Technological advancements are enabling more accurate expression profiling of PD-L1 in tumor cells. New companion diagnostics allow for more precise patient selection and better response rates to atezolizumab therapy. Biomarker research is also exploring combinations of atezolizumab with chemotherapy or other immunotherapies for expanded treatment benefits. Market Trends The shift towards personalized medicine is a key trend in the atezolizumab market. With the help of companion diagnostics, doctors are better able to determine patients that are likely to respond to atezolizumab therapy based on tumor PD-L1 levels. This allows for targeting treatment to those who will benefit the most. Combination therapies involving atezolizumab are gaining popularity due to improved clinical outcomes. Pairing with chemotherapy or other checkpoint inhibitors like nivolumab provides opportunities for synergistic anti-tumor effects. Several ongoing clinical trials are evaluating combination regimens. Market Opportunities The approval of atezolizumab for additional cancer types beyond NSCLC presents major commercial opportunities. Ongoing studies are exploring its efficacy for bladder, breast, lung, gastric and other cancers. Impact of COVID-19 on Atezolizumab Market Growth The post-COVID scenario is expected to see higher growth. With resumption of cancer treatment procedures and launch of new clinical trials evaluating efficacy of atezolizumab in combination with other drugs, its sales are projected to rise steadily in the coming years. Additionally, the pandemic has led to greater investments into cancer immunotherapy research by both government as well private organizations which is anticipated to boost market growth. It is important for key players to enhance supply chain management and ensure continuous supply of atezolizumab to cater to the increasing demand from cancer patients globally in the post-COVID era. In terms of geographical regions, North America accounts for the largest share of the atezolizumab market in terms of value. This is attributed to several factors like rising prevalence of cancer, high healthcare spending, widespread awareness about cancer immunotherapy, and presence of major market players in the region. Asia Pacific is poised to be the fastest growing region for the atezolizumab market during the forecast period owing to growing cases of cancer, increasing healthcare expenditures of people, and expansion strategies of market players in emerging countries.

[blog-site-for-market-research]

Surgical Site Infection Control Market Size, Share & Trends Analysis Report

Market Synopsis

The Surgical Site Infection Control Market is estimated to grow at a 5.80% CAGR between 2022 and 2030, reaching USD 4969.21 million.

The rise in hospital-acquired infections is predicted to be a key factor driving the global surgical infection market 2020. The rising incidence of chronic illnesses like cancer, heart-related diseases, and others are likely to create a significant need for surgical infection control methods, which can augment the market during the forecast period. Furthermore, the increasing number of surgeries with the growing geriatric population is projected to increase the need for surgical infection controlling ways that can favor the market growth during the forecast period.

On the contrary, the lack of awareness of hospital infection can impede market growth in the coming period. However, the growing number of surgeries, along with  above-mentioned factors can counter the hampering factor and boost the market.

Market Segmentation

The segmental analysis of the global surgical infection control market is done by procedure, product, end-user, and type of infection.

The procedure-based segments of the global surgical infection control market are gastric bypass, caesarean section, cataract surgery, dental restoration, and others.

The product-based segments of the global surgical infection control market are disinfectants, manual reprocesses solution, surgical scrubs, surgical gloves, skin preparation solution, surgical drapes, medical nonwovens, and others. The disinfectants is further segmented into hand disinfectants and skin disinfectants.

The end user-based segments of the global surgical infection control market are hospitals and ambulatory surgical centres.

The type of infection based segments of the global surgical infection control market are deep incisional SSI organ or space SSI and superficial incisional SSI.

Regional Analysis

Based on the region, the global live cell imaging market is segmented into Europe, North America, Asia-Pacific, and the Rest of the World (RoW).

As per the analysis, the Americas is likely to dominate the global surgical infection control market owing to the significant investments in research and development programs. Furthermore, advanced healthcare infrastructure is likely to boost the regional market during the evaluation period. The growing incidence of chronic illness in the region is anticipated to be another notable factor in growing the regional market.

Europe is predicted to be the second-largest market during the forecast period owing to the growing awareness regarding hygiene and sanitation. In addition, the growing government initiatives to prevent infections is another significant cause fueling the regional market. However, the implementation of stringent rules and regulations can hamper market growth during the review period.

The APAC region is predicted to be the fastest-growing market during the forecast period due to lucrative opportunities. Emerging nations like India and China are anticipated to play a notable role due to the fast adoption of the latest technologies. Besides, the government of various nations present in the APAC region is likely to improve healthcare services, which can propel the regional market.

The MEA region is anticipated to acquire the least market share during the review period due to the presence of under-developed nations. However, the presence of untapped opportunities can fuel market growth in the coming period. Besides, Middle East countries' participation can prove to be profitable for the expansion of the regional market.

Key Players

Some of the renowned players of the global surgical site infection control market research are Becton Dickinson and Company, 3M, Belimed AG, bioMerieux SA, Johnson & Johnson, Getinge Group, Kimberly-Clark Corporation, Ansell Limited, Sotera Health, Steris Corporation, Pacon Manufacturing Corp, Lac-Mac Limited, American Polyfilm Inc., and others.

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: sales@marketresearchfuture.com

Website: https://www.marketresearchfuture.com

[futuretonext]

The Global Gastric Cancer Treatments Market is projected to grow at a CAGR of around 14.80% during the forecast period, i.e., 2022-27. The market is driven by the rapidly increasing number of people suffering from Gastric Cancer and rapid developments in the healthcare sector offering quicker diagnosis & effective treatments for the same.

[market-insider]

Gastro Diagnostics Uncovered: Industry Analysis and Opportunity Assessment

The global gastrointestinal diagnostics market size is expected to reach USD 6.87 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 4.58% from 2022 to 2030. Rising awareness about gastrointestinal disorders and a surge in gastrointestinal disorder testing are the major factors driving the market. Moreover, technological advancements in gastrointestinal infection testing are expected to cater to the market demand. For instance, in May 2022, QIAGEN launched QIAstat-Dx Rise, which is capable of providing results in one hour for multiple diseases.

Gastrointestinal Diagnostics Market Report Highlights

Based on test type, the endoscopy segment held the largest share in 2021 owing to rising demand for minimally invasive procedures

Based on technology, the PCR accounted for the second-largest share in 2021 due to the availability of a robust product portfolio and rising product launches

The infection application segment held the largest share in 2021 owing to the higher incidence of GI infections and the surge in awareness

Based on test location, the central laboratories segment held the largest share in 2021. The point-of-care segment is anticipated to register the fastest growth rate throughout the forecast period

Asia Pacific is expected to exhibit the fastest growth rate over the forecast period due to the rising investments by market players and increasing research activities in the region

For More Details or Sample Copy please visit link @: Gastrointestinal Diagnostics Market Report

The increasing trend of a sedentary lifestyle, lack of exercise, unhealthy eating habits, and a higher prevalence of obesity are anticipated to fuel GI diagnostics market growth. According to the CDC, the prevalence of obesity among people in the U.S. is between 30-40%. States such as Alabama, Alaska, and Arizona have the highest prevalence of obesity in the U.S. Obesity is associated with GI diseases such as gastroesophageal reflux disease, diarrhea, gastric cancer, and others. Hence, it is expected to impetus market growth.

Technological advancements associated with gastrointestinal diagnostics for early diagnosis and efficient testing are expected to augment market growth during the forecast period. For instance, in March 2022, Luminex Corporation obtained a CE mark for its NxTAGxMAP GI Pathogen Panel. This test is a detailed multiplex test that detects nucleic acids from the 16 most clinically relevant viral, parasitic, and bacterial pathogens in stool samples. Moreover, the test is capable of providing results on the same day and can run 96 samples at a time.